Jump to content

ConjuChem

Add links
From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by SimLibrarian (talk | contribs) at 06:17, 20 December 2023. The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
ConjuChem Biotechnologies Inc.
Company typePublic (TSX has Delisted this Stock)
IndustryBiotechnology
Headquarters
Montreal, Quebec
,
Canada
Key people
Mark Perrin
ProductsDrug Affinity Construct (DAC) and Preformed Conjugate-Drug Affinity Construct (PC-DAC)
Number of employees
44[citation needed][needs update]
Websitewww.conjuchem.com

ConjuChem Biotechnologies Inc. is a medical biotechnology company located in Montreal, Quebec, Canada[1] which is credited with inventing the experimental peptide hormone CJC-1295.[2][3]

It employs 45 people, 90% of whom are in research and development.[citation needed][needs update]

References

[edit]
  1. ^ "Conjuchem Biotechnologies Inc". Bloomberg Business. Retrieved 18 June 2015.
  2. ^ Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". The Journal of Clinical Endocrinology & Metabolism. 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X. PMID 16352683.
  3. ^ "CJC-1295 or Modified GRF (1-29)". American Science Labs. 9 February 2015. Archived from the original on 18 June 2015. Retrieved 18 June 2015.
[edit]


Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ConjuChem&oldid=1190851434"